罗沙司他、人促红素注射液用于血液透析患者的效果比较  

Comparison of the effect of roxadustat and human erythropoietin injection in hemodialysis patients

作　　者：沙娜 吴军玲 付纲[2] 王梦祎 张藜莉 SHA Na;WU Junling;FU Gang;WANG Mengyi;ZHANG Lili(Department of Pharmacy,Emergency General Hospital,Beijing 100028,China;Department of Nephrology,Beijing Haidian Hospital,Beijing 100080,China;Department of Nephrology,Beijing Chaoyang Hospital Affiliated to Capital Medical University,Beijing 100020,China)

机构地区：[1]应急总医院药学部,北京100028 [2]北京市海淀医院肾内科,北京100080 [3]首都医科大学附属北京朝阳医院肾内科,北京100020

出　　处：《药学前沿》2024年第11期465-471,共7页China Pharmacist

基　　金：北京市海淀医院2020年院级科研基金项目(KYM2020002)。

摘　　要：目的分析罗沙司他、人促红素注射液用于血液透析患者的效果。方法选取2021年12月至2023年12月于应急总医院进行血液透析治疗的患者资料,根据治疗方案分为试验组(罗沙司他口服)和对照组(人促红素注射液皮下注射)。比较两组血红蛋白(Hb)、血细胞比容(HCT)、促红细胞生成素(EPO)、转铁蛋白饱和度(TSAT)、不饱和铁结合力(UIBC)、铁蛋白(SF)、成纤维细胞生长因子-23(FGF-23)、NADPH氧化酶2(NOX2)、晚期蛋白氧化产物(AOPP)、P-选择素(CD62P)、C反应蛋白(CRP)、白细胞介素(IL)-1β、IL-6、紧密连接跨膜蛋白(CLDN1)水平和不良反应发生情况。结果研究共纳入80例患者,每组各40例。治疗后,试验组患者Hb、HCT、SF、TSAT、CLDN1水平高于对照组,且EPO、UIBC、FGF-23、AOPP、NOX2、CD62P、CRP、IL-Iβ、IL-6水平低于对照组(P<0.05)。试验组不良反应发生率低于对照组(P<0.05)。结论相较于人促红素注射液,罗沙司他可明显纠正血液透析患者贫血状态,调节铁代谢,改善炎症、氧化应激反应,具有较高有效性和安全性。Objective To analyze the effect of roxadustat and human erythropoietin injection on hemodialysis patients.Methods Data of the patients who received hemodialysis treatment in Emergency General Hospital from December 2021 to December 2023 were selected and the patients were divided into the test group(treated with oral roxadustat)and the control group(treated with human erythropoietin subcutaneous injection)according to the treatment schemes.The levels of hemoglobin(HB),hematocrit(HCT),erythropoietin(EPO),transferrin saturation(TSAT),unsaturated iron binding capacity(UIBC),ferritin(SF),fibroblast growth factor-23(FGF-23),NADPH oxidase 2(NOX2),advanced protein oxidation product(AOPP),P-selectin(CD62P),C-reactive protein(CRP),interleukin-1β(IL-1β),interleukin-6(IL-6),claudin-1(CLDN-1)and the incidence of adverse reactions were compared between the two groups.Results A total of 80 patients were included,with 40 patients in each group.After treatment,the levels of Hb,HCT,SF,TSAT and CLDN-1 in the test group were higher than those in the control group,while the levels of EPO,UIBC,FGF-23,AOPP,NOX2,CD62P,CRP,IL-1βand IL-6 in the test group were lower than those in the control group(P<0.05).The incidence of adverse reactions in the test group was lower than that in the control group(P<0.05).Conclusion Compared with human erythropoietin injection,roxadustat can significantly correct the anemia state of hemodialysis patients,regulate the iron metabolism,improve the inflammation and the oxidative stress response,and has high effectiveness and safety.

关 键 词：罗沙司他 重组人促红素注射液 血液透析 血红蛋白 铁代谢 贫血 

分 类 号：R969.4[医药卫生—药理学]